Initiation projectWGS · NASDAQ
Can GeneDx turn its rare-disease data advantage into durable profitability?
A developing thesis on genomic diagnostics, AI-assisted interpretation and the economics of moving exome and genome sequencing earlier in pediatric care.
Research in progressUpdated August 5, 2026
Open research project →Q2 2026 snapshotCompany reported
Revenue$114.4M11% year over year
Exome + genome volume30,78532% year over year
Adjusted gross margin70%68% GAAP
2026 revenue guide$475–490M≥30% volume growth
Source: GeneDx Q2 2026 results. Figures are not forecasts or recommendations.